New Resource Bank

The Federal Home Loan Bank of Dallas and Members Award More Than $160K to 13 Louisiana Community Organizations

Retrieved on: 
Thursday, September 28, 2023
Other Philanthropy, Construction & Property, Finance, Banking, Professional Services, Philanthropy, Other Construction & Property, Residential Building & Real Estate, Federal Home Loan Bank Board, Partnership, Home Bank, FHLB, New Resource Bank, Fidelity Bank, Federal Home Loan Banks, United States African Development Foundation, National Trust Community Investment Corporation, PGP, CRA, BankPlus Amphitheater, Growth, First Bank and Trust, Citizens Bank, Commerce, Petroleum

Louisiana community-based organizations received $160,250 from the Federal Home Loan Bank of Dallas (FHLB Dallas) and 14 member institutions.

Key Points: 
  • Louisiana community-based organizations received $160,250 from the Federal Home Loan Bank of Dallas (FHLB Dallas) and 14 member institutions.
  • A total of $557,250 was awarded to community organizations through its annual Partnership Grant Program (PGP).
  • “With its matching funds, our Partnership Grant Program gives our members added leverage to support local nonprofits,” said Greg Hettrick, senior vice president and director of Community Investment at FHLB Dallas.
  • For more information about the 2023 PGP grants and other FHLB Dallas community investment products and programs, please visit fhlb.com/pgp .

 VBI Vaccines Announces Poster Presentation at EASL 2023

Retrieved on: 
Wednesday, June 7, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, News, Volunteering, EASL, Vaccination, European Association for the Study of the Liver, ILC, MSL, Medical science liaison, VBI, Syneos Health, Poster, Annual general meeting, Vaccine, HBV, New Resource Bank, PROTECT, Disease, Liver

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting T-cell responses and durability of immune responses following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine, PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], has been accepted for poster presentation at The International Liver Congress™ 2023 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place June 21-24.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting T-cell responses and durability of immune responses following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine, PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], has been accepted for poster presentation at The International Liver Congress™ 2023 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place June 21-24.
  • Title: T-cell responses to Pre-S1 and Pre-S2 are correlated to anti-HBs antibody titers, which are higher and persist longer in volunteers vaccinated with 3-antigen than with 1-antigen hepatitis B vaccine in the PROTECT Study: 3.5 year follow up
    Session: Poster – Viral hepatitis B and D: Clinical aspects
    Presenter: Andrew Boyle, Medical Science Liaison (MSL) U.K., employed at Syneos Health on behalf of VBI
    Following the conference, the poster will be archived on the Posters page in the News & Resources section of VBI’s website, here .

Triumvira Immunologics to Present New Data on its TAC T Cell Autologous and Allogeneic Products and the Ongoing Phase I/II Solid Tumor Trial at the 2023 AACR Annual Meeting

Retrieved on: 
Wednesday, March 15, 2023
Cancer, AACR, Presentation Public School, HER2, News, Abstract (summary), Patient, New Resource Bank, Safety, White, Therapy, Pharmaceutical industry

The presentations will include updated clinical data and product characterization from the ongoing Phase I/II trial of autologous TAC01-HER2 ( NCT04727151 ) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.

Key Points: 
  • The presentations will include updated clinical data and product characterization from the ongoing Phase I/II trial of autologous TAC01-HER2 ( NCT04727151 ) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.
  • Further, we will present new preclinical data from our allogeneic T cell-based products in development demonstrating their potential to avoid graft versus host disease."
  • Abstracts are currently available on the AACR website .
  • A copy of the presentations will also be available after the closure of the meeting on April 19, under the Presentations & Publications tab of the News & Resources section of the Company's website .

ExxonMobil Announces Corporate Plan

Retrieved on: 
Thursday, December 8, 2022
Chemicals, Plastics, Energy, Manufacturing, Oil, Gas, Carbon, Permian, Maintenance, Capital, Supplement, Norris Production Solutions, ExxonMobil, Cautionary tale, API, Transport, Energy factor, Environment, Sale, Calumet Specialty Products Partners, Natural gas, Annual report, Biofuel, Nationalization, Research, LNG, Investment, Government, Quality of life, Policy, COVID-19, News, American Petroleum Institute, New Resource Bank, Safety, Risk, Frequentative, Public expenditure, Lubricant, Hydrogen, Tax, Henry Hub, Climate change, Seizure, Insurance, Renewable energy, Oil, Petroleum, IPIECA, Chemical substance, Upstream

ExxonMobil today announced its corporate plan for the next five years, with a sizeable increase in investments aimed at emission reductions and accretive lower-emission initiatives, including its Low Carbon Solutions business.

Key Points: 
  • ExxonMobil today announced its corporate plan for the next five years, with a sizeable increase in investments aimed at emission reductions and accretive lower-emission initiatives, including its Low Carbon Solutions business.
  • The corporate plan through 2027 maintains annual capital expenditures at $20-$25 billion, while growing lower-emissions investments to approximately $17 billion.
  • The corporate plan were laying out today reflects that view, and the results weve seen to date demonstrate that were on the right course.
  • By year-end 2022, ExxonMobil expects to distribute approximately $30 billion to shareholders, including $15 billion in dividends and $15 billion in share repurchases.

Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress

Retrieved on: 
Tuesday, September 6, 2022
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Technology, New Resource Bank, Abstract (summary), News, TAC, Synthetic immunology, European Society for Medical Oncology, EDT, ESMO, Presentation Public School, Congress, HER2, Paris Expo Porte de Versailles, Therapy, Oncology, CEST, TCR, Patient, Vaccine

TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).

Key Points: 
  • TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).
  • Location: Paris Expo Porte de Versailles, Hall 4
    Abstracts will be published online on the ESMO website at 12:05 a.m. CEST on Sept. 5, 2022 (6:05 p.m. EDT on Sept. 4, 2022).
  • Triumvira Immunologics, Inc. (Triumvira) is a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors.
  • The companys proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies.

Aspiration Introduces Tim Newell as Company’s First Chief Innovation Officer

Retrieved on: 
Thursday, August 4, 2022
Finance, Banking, Environment, Professional Services, Sustainability, Well, SolarCity, Movement, TIM, Multimedia, Warburg Pincus, Technology policy, Office of Science and Technology Policy, Los Angeles Clippers, CEO, Newell, NYSE, Fourth Estate Public Benefit Corporation, Tesla, Technology, Lucent, Science and technology in Asia, Leadership, White House, Board, Verifone, Chief executive officer, Acquisition, Do Good, Draper Fisher Jurvetson, White, Boston Red Sox, Policy, Life Partners, Inc., New Resource Bank, Professional corporation, Aspiration, Inc., Organization, Deloitte, Management, Renewable energy, Aspiration, Science, Sustainability, Lime, Director, Economics, Finance, Banking, Environment, Professional Services, Sustainability

Aspiration, a global leader in Sustainability as a Service solutions for consumers and companies, today announced that technology and sustainability veteran Tim Newell has joined the company as its very first Chief Innovation Officer.

Key Points: 
  • Aspiration, a global leader in Sustainability as a Service solutions for consumers and companies, today announced that technology and sustainability veteran Tim Newell has joined the company as its very first Chief Innovation Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220804005383/en/
    Tim Newell, Aspiration Chief Innovation Officer (Photo: Business Wire)
    Aspiration stands on the shoulders of the important work that leaders like Tim have been doing at the intersection of finance, technology, and sustainability for years, said Andrei Cherny, CEO and co-founder of Aspiration.
  • Most recently, Newell oversaw financial product design and development for companies such as SolarCity, Tesla, and Better.com.
  • Aspiration is a leading platform to help people and businesses put automated sustainable impact into their hands and integrate it into their daily lives.

Robertson “Clay” Jones Named President and Chief Executive Officer of Heritage Commerce Corp

Retrieved on: 
Thursday, July 28, 2022
CA, Time, GLOBE, Heritage Bank, Board of directors, Comerica, Â, SAN, San Francisco Bay Area, Commerce, Bank, Board, Organization, New Resource Bank, Director, Company, Nasdaq, SBA, Growth, Management, Security (finance)

At that time, Robertson Clay Jones, currently President and Chief Operating Officer of the Bank, will succeed him and become the President and Chief Executive Officer of the Company and the Bank.

Key Points: 
  • At that time, Robertson Clay Jones, currently President and Chief Operating Officer of the Bank, will succeed him and become the President and Chief Executive Officer of the Company and the Bank.
  • We very much appreciate his willingness to return as Chief Executive Officer in March 2021, as we developed a transition plan that would lead the Company into the future.
  • Mr. Jones joined the Bank in 2019 as Executive Vice President, President of Community Business Banking.
  • He was named President and Chief Operating Officer in 2021 and has been a key contributor to the Banks growth and success.

VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022

Retrieved on: 
Thursday, May 19, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Disease, HBV, VLP, Infection, Cirrhosis, Liver cancer, Allergy, Virus, VBI, Poster, Private Securities Litigation Reform Act, Headache, Immune system, SEC, Fatigue, Annual report, Anaphylaxis, Pharmacoeconomics, CMV, International Society, Pain, Woman, Outcomes research, Nature, European, COVID-19, Research, Immunodeficiency, GBM, Company, Hepatitis B, Health Economics, Myalgia, New Resource Bank, International Society for Pharmacoeconomics and Outcomes Research, VAERS, Hepatocellular carcinoma, Pregnancy, Hepatitis B virus, Tenderness, History, Nasdaq, Patient, EU, Cytomegalovirus, Vaccine, Industry, Liver disease, Glioblastoma, Person, News, Medicine, Birth control

Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.

Key Points: 
  • Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.
  • An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

Southern California Health & Rehabilitation Program's 45th Street Apartments to Be Renamed in Honor of Trailblazing Homeless Advocate Ruth Schwartz

Retrieved on: 
Tuesday, March 15, 2022
Mental health, GLOBE, United States Public Health Service, Housing, 2009 Davis Cup, New Resource Bank, Los Angeles County Department of Health Services, Mendocino County GMO Ban, HHH, Proposition, Los Angeles County Department of Mental Health, Life, Schwartz, Person, Rehabilitation, CEO, Population, Homelessness, Housing First, Policy, Bridge

Schwartz was a dynamic figure in the fight to ease the suffering of homeless persons in Los Angeles County.

Key Points: 
  • Schwartz was a dynamic figure in the fight to ease the suffering of homeless persons in Los Angeles County.
  • "She was homelessness before Measure H, Proposition HHH, and the ad hoc committee on Black homelessness," said Jack Barbour, Chief Executive Officer of SCHARP.
  • SCHARP was founded in February 1994 as a nonprofit to provide mental health services to vulnerable ethnic minority populations in South Los Angeles.
  • The 45th Street Apartments is one of those now rehabilitated buildings that is home to persons who had experienced homelessness.The building will be renamed The Ruth Schwartz Apartments.

ExxonMobil Details Plans to Lead in Earnings and Cash Flow Growth, Energy Transition

Retrieved on: 
Wednesday, March 2, 2022
Oil, Gas, Environment, Alternative Energy, Public Relations, Investor Relations, Energy, Communications, Chemicals, Plastics, Manufacturing, Permian, Carbon, Zero, Energy factor, Public expenditure, Investment, Outlook, Industry, Policy, IPIECA, Investor, API, Lubricant, Forward-looking statement, Government, Safety, American Petroleum Institute, World Energy Outlook, Solution, Biofuel, Pandemic, Cautionary Tales (Heroes), Goal, Company, Time, Methane, Supplement, Economic development, Hydrogen, Tax, Environment, Guyana, ExxonMobil, Petroleum, Risk, Technology, News, New Resource Bank, Health, Frequentative, Renewable energy, Oil, Risk management, Chemical substance, LNG

The 2021 results enabled repayment of about $20 billion in debt -- nearly all of the debt borrowed during the pandemic downturn, the 39th consecutive year of dividend increases, and a $10 billion share-repurchase program that started earlier this year.

Key Points: 
  • ExxonMobil today detailed plans at its annual Investor Day to deliver industry-leading earnings, cash flow growth and shareholder returns, and lead in the energy transition across a range of lower-emissions scenarios.
  • To improve future earnings, ExxonMobil is upgrading its portfolio with low-cost-of-supply opportunities by investing in advantaged assets, including Guyana and the U.S. Permian Basin.
  • ExxonMobil, one of the largest publicly traded international energy companies, uses technology and innovation to help meet the worlds growing energy needs.
  • Outlooks; projections; goals; ambitions; estimates; discussions of earnings, cash flow, margins, rate of return, and recoverable resources; and descriptions of strategic plans and objectives are forward-looking statements.